Genome-wide analysis of hepatic lipid content in extreme obesity

Acta Diabetologica

Volumn 52, Issue 2, 2014, Pages 373-382

  DiStefano, Johanna K ^a   Kingsley, Christopher ^a   Craig Wood, G ^b   Chu, Xin ^b   Argyropoulos, George ^b   Still, Christopher D ^b   Doné, Stefania Cotta ^a   Legendre, Christophe ^a   Tembe, Waibhav ^a   Gerhard, Glenn S ^b,c  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Bilirubin; Hepatic lipid; LPAR2; Obesity; PNPLA3; SOCS2

Indexed keywords

BILIRUBIN; RAMP3 PROTEIN, HUMAN; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; SOCS2 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADULT; COMPLICATION; FEMALE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; LIPID METABOLISM; LIVER; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BILIRUBIN; DIABETES MELLITUS, TYPE 2; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LIPID METABOLISM; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR ACTIVITY-MODIFYING PROTEIN 3; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84939949211     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0654-3     Document Type: Article

References (50)

1. Wang Y, Li YY, Nie YQ, Zhou YJ, Cao CY, Xu L (2013) Association between metabolic syndrome and the development of non-alcoholic fatty liver disease. Exp Ther Med 6:77–84
2. Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679–689
3. Birkenfeld AL, Shulman GI (2014) Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59:713–723
4. Day CP (2006) Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int Off J Int Assoc Study Liver 26:1021–1028
5. Machado M, Marques-Vidal P, Cortez-Pinto H (2006) Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45:600–606
6. Browning JD, Kumar KS, Saboorian MH, Thiele DL (2004) Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 99:292–298
7. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE (2002) Is NASH underdiagnosed among African Americans? Am J Gastroenterol 97:1496–1500
8. Struben VM, Hespenheide EE, Caldwell SH (2000) Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 108:9–13
9. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA (2001) Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 96:2957–2961
10. Schwimmer JB, Celedon MA, Lavine JE et al (2009) Heritability of nonalcoholic fatty liver disease. Gastroenterology 136:1585–1592
11. Wilfred de Alwis NM, Day CP (2008) Genes and nonalcoholic fatty liver disease. Curr DiabRep 8:156–163
12. Romeo S, Kozlitina J, Xing C et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465
13. Hotta K, Yoneda M, Hyogo H et al (2010) Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 11:172
14. Kantartzis K, Peter A, Machicao F et al (2009) Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58:2616–2623
15. Petit JM, Guiu B, Masson D et al (2011) PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes. Liver Int Off J Int Assoc Study Liver 31:1332–1336
16. Romeo S, Sentinelli F, Dash S et al (2010) Morbid obesity exposes the association between PNPLA3 I148 M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond) 34:190–194
17. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ (2010) The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52:894–903
18. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ (2009) A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 50:2111–2116
19. Wang CW, Lin HY, Shin SJ et al (2011) The PNPLA3 I148 M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int Off J Int Assoc Study Liver 31:1326–1331
20. Liew PL, Lee WJ, Wang W et al (2008) Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes Surg 18:847–853
21. Chisholm J, Seki Y, Toouli J, Stahl J, Collins J, Kow L (2012) Serologic predictors of nonalcoholic steatohepatitis in a population undergoing bariatric surgery. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 8:416–422
22. Dong H, Huang H, Yun X et al (2014) Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of er stress and chronic inflammation. Endocrinology 155:818–828
23. Cox AJ, Ng MC, Xu J et al (2013) Association of SNPs in the UGT1A gene cluster with total bilirubin and mortality in the Diabetes Heart Study. Atherosclerosis 229:155–160
24. Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321
25. Wood GC, Chu X, Manney C et al (2012) An electronic health record-enabled obesity database. BMC Med Inform Decis Mak 12:45
26. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O’Donnell CJ, de Bakker PI (2008) SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24:2938–2939
27. Still CD, Craig Wood G, Chu X, et al (2013) Clinical factors associated with weight loss outcomes after Roux-en-Y gastric bypass surgery. Obesity (Silver Spring) 22(3):888–894
28. Speliotes EK, Yerges-Armstrong LM, Wu J et al (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7:e1001324
29. Dai X, Wu C, He Y et al (2013) A genome-wide association study for serum bilirubin levels and gene-environment interaction in a Chinese population. Genet Epidemiol 37:293–300
30. Chen G, Ramos E, Adeyemo A et al (2012) UGT1A1 is a major locus influencing bilirubin levels in African Americans. Eur J Human Genet 20:463–468
31. Johnson AD, Kavousi M, Smith AV et al (2009) Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 18:2700–2710
32. Kitamoto T, Kitamoto A, Yoneda M et al (2013) Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 132:783–792
33. Chalasani N, Guo X, Loomba R, et al. (2010) Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology 139:1567–1576, 1576 e1561–1566
34. Speliotes EK, Butler JL, Palmer CD et al (2010) PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52:904–912
35. Gorden A, Yang R, Yerges-Armstrong LM et al (2013) Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Hum Hered 75:34–43
36. Verrijken A, Beckers S, Francque S et al (2013) A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity 21:2138–2145
37. Gordon L, Joo JE, Powell JE et al (2012) Neonatal DNA methylation profile in human twins is specified by a complex interplay between intrauterine environmental and genetic factors, subject to tissue-specific influence. Genome Res 22:1395–1406
38. Kozlitina J, Smagris E, Stender S et al (2014) Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46:352–356
39. Rancoule C, Attane C, Gres S et al (2013) Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice. Diabetologia 56:1394–1402
40. Sankella S, Garg A, Horton JD, Agarwal AK (2014) Hepatic gluconeogenesis is enhanced by phosphatidic acid which remains uninhibited by insulin in lipodystrophic Agpat2-/- mice. J Biol Chem 289:4762–4777
41. Kumashiro N, Yoshimura T, Cantley JL et al (2013) Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology 57:1763–1772
42. Kashyap SR, Diab DL, Baker AR et al (2009) Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring) 17:1696–1701
43. Rasche A, Al-Hasani H, Herwig R (2008) Meta-analysis approach identifies candidate genes and associated molecular networks for type-2 diabetes mellitus. BMC Genom 9:310
44. Zadjali F, Santana-Farre R, Vesterlund M et al (2012) SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high-fat-diet-fed mice. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 26:3282–3291
45. Tateno C, Kataoka M, Utoh R et al (2011) Growth hormone-dependent pathogenesis of human hepatic steatosis in a novel mouse model bearing a human hepatocyte-repopulated liver. Endocrinology 152:1479–1491
46. Lebrun P, Cognard E, Gontard P et al (2010) The suppressor of cytokine signalling 2 (SOCS2) is a key repressor of insulin secretion. Diabetologia 53:1935–1946
47. Elam MB, Cowan GS Jr, Rooney RJ et al (2009) Hepatic gene expression in morbidly obese women: implications for disease susceptibility. Obesity 17:1563–1573
48. Westermark GT, Westermark P (2013) Islet amyloid polypeptide and diabetes. Curr Protein Pept Sci 14:330–337
49. Lutz TA (2010) The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol 298:R1475–R1484
50. Ye JM, Lim-Fraser M, Cooney GJ et al (2001) Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance. American journal of physiology Endocrinology and metabolism 280:E562–E569